{"id":"66a57cd2-4228-4a65-af6a-e99ce5c92401","slug":"linezolid-for-the-treatment-of-postneurosurgical-infection-caused-by-methicillin-resistant-staphylococcus","title":"Linezolid for the treatment of postneurosurgical infection caused by methicillin-resistant <i>Staphylococcus</i>","authors":["Lotfi Rebai","Nizar Fitouhi","Mohamed Aziz Daghmouri","Kamel Bahri"],"abstract":"Background: Postneurosurgical infection (PNSI) is a major problem. Linezolid is a bacteriostatic oxazolidinone antibiotic with a highly activity against Gram-positive cocci resistant to methicillin and a good cerebrospinal fluid penetration. The purpose of this study is to evaluate the efficacy of linezolid in the treatment of PNSI caused by methicillin-resistant Staphylococcus (MRS). Methods: We conducted an observational study for all patients over 14 years old and diagnosed with MRS PNSI. Demographic, clinical, and laboratory information were collected prospectively. Results: A total of 10 patients with PNSI (6 meningitis, 2 ventriculitis, and 2 subdural empyema) received linezolid. MRS isolated was Staphylococcus aureus in seven cases and Staphylococcus epidermidis in three cases. All isolated microorganisms were susceptible to vancomycin (minimum inhibitory concentration (MIC) = 2 mg/L) and linezolid (MIC = 1). The rate of microbiologic efficacy was 100% for patients with meningitis or ventriculitis. In the case of subdural empyema, focal infection had improved between 14 and 18 days. No adverse effects occurred during this study. Conclusion: Our results suggest that linezolid as an alternative to vancomycin for the treatment of PNSI caused by MRS with a high rate of efficacy.","thumbnailUrl":"https://sni-digital-videos.s3.amazonaws.com/articles/66a57cd2-4228-4a65-af6a-e99ce5c92401/featured/hero-1781563718056.png","publishDate":"2019-11-08T00:00:00.000Z","doi":"10.25259/SNI_455_2019","categories":["Infection","Original Article"],"fullTextUrl":"https://surgicalneurologyint.com/api/articles/66a57cd2-4228-4a65-af6a-e99ce5c92401/pdf"}